ESMO ADVANCED COURSE PROGRAMME

EGFR IN LUNG CANCER

Hong Kong SAR, China
26-27 January 2024

CO-CHAIRS
Tony S. K. Mok, Hong Kong SAR, China
Solange Peters, Switzerland

SPEAKERS
Lyudmila Bazhenova, United States
Enriqueta Felip, Spain
Rina Hui, Hong Kong SAR, China
Keith M. Kerr, United Kingdom
Molly S. C. Li, Hong Kong SAR, China
David Planchard, France
Suresh S. Ramalingam, United States
Daniel S. W. Tan, Singapore
James C.-H. Yang, Taiwan
Pan-Chyr Yang, Taiwan
Thomas Y.-L. Wu, China

LEARNING OBJECTIVES

• To understand the role of molecular diagnostic test on tissue and plasma samples for diagnosis, monitoring and TKI resistance in management of epidermal growth factor receptor (EGFR) mutation positive (M+) lung cancer
• To comprehend management of early stage and local advanced EGFR M+ lung cancer
• To gain updated information on optimal first line management and treatment of TKI resistance
• To interrogate the potential use of immunotherapy for patients with EGFR M+ lung cancer

ACCREDITATION

The programme of this event has been accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org
Friday, 26 January 2024

09:00-09:10  Welcome and introduction
  Tony S. K. Mok, HKSAR CN
  Solange Peters, CH

09:10-10:25  Session 1 – Diagnosis and early detection
  (Chair: Keith M. Kerr, UK)
  20’ Biomarker testing for NSCLC: Why should it be comprehensive and/or reflex?  
    Keith M. Kerr, UK
  20’ The role of liquid biopsy in management of EGFR M+ lung cancer: Initial diagnosis, monitoring and resistance  
    Molly S. C. Li, HKSAR CN
  20’ Early detection of lung cancer among never smokers  
    Pan-Chyr Yang, TW
  15’ Discussion

10:25-10:55  Coffee break

10:55-11:50  Session 2 – Optimal standard of care
  (Chair: Solange Peters, CH)
  20’ The art of optimal first-line therapy for patients with sensitizing or uncommon EGFR M+ lung cancer  
    Tony S. K. Mok, HKSAR CN
  20’ Potential combination therapy for EGFR M+ lung cancer  
    Rina Hui, HKSAR CN
  15’ Discussion

11:50-12:45  Session 3 – EGFR TKI resistance
  (Chair: Tony S. K. Mok, HKSAR, China)
  20’ Understanding and overcoming resistance to EGFR TKI: Mechanisms and dynamics  
    David Planchard, FR
  20’ Treatment strategy for management EGFR TKI resistance  
    Lyudmila Bazhenova, US
  15’ Discussion

12:45-13:45  Lunch

13:45-15:00  Session 4 – Early EGFR M+ NSCLC
  (Chair: Daniel S. W. Tan, SG)
  20’ Adjuvant therapy for resectable EGFR M+ lung cancer  
    Thomas Y.-L. Wu, CN
  20’ How to manage stage III EGFR M+ lung cancer  
    Suresh S. Ramalingam, US
Next generation neo-adjuvant and adjuvant trials in EGFR M+ and other oncogene addicted lung cancer (excluding IO)
Enriqueta Felip, ES

Discussion

15:00-15:30 Coffee break

15:30-16:50 Session 5 – Facing the uncertainties
(Chair: Suresh S. Ramalingam)

25’ Role of IO in early and advanced stage EGFR M+ lung cancer
Solange Peters, CH

20’ Biology and impact of co-mutations on management of EGFR M+ lung cancer
Daniel S. W. Tan, SG

20’ Novel treatment approaches to EGFR M+ lung cancer
James C.-H. Yang, US

15’ Discussion and closure of the day

19:00 Networking dinner

Saturday, 27 January 2024

09:00-12:30 Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all sessions on a rotation basis)

25’ Introduction based on clinical cases presented by speakers

30’ Discussion

5’ Break

Workshop 1 Oligometastasis, oligoprogression and systemic progression: How best to address
60’
Molly S. C. Li, HKSAR CN
Suresh S. Ramalingam, US

Workshop 2 Interrogations for early stage EGFR M+ NSCLC
60’
David Planchard, FR
Rina Hui, HKSAR CN

Workshop 3 Prevention and management of brain and leptomeningeal metastases
60’
Daniel S. W. Tan, SG
James C.-H. Yang, TW

11:00-11:30 Coffee break
11:30-12:30  Workshops continuation

12:30-13:00  Synthesis and wrap-up
Tony S. K. Mok, HKSAR CN
Solange Peters, CH

13:00-14:00  Lunch